BerGenBio ASA

Oslo Stock Exchange BGBIO.OL

BerGenBio ASA Price to Sales Ratio (P/S) on January 14, 2025: 867.57

BerGenBio ASA Price to Sales Ratio (P/S) is 867.57 on January 14, 2025, a -59.76% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

BerGenBio ASA 52-week high Price to Sales Ratio (P/S) is 91,346.98 on May 24, 2024, which is 10,429.05% above the current Price to Sales Ratio (P/S).
BerGenBio ASA 52-week low Price to Sales Ratio (P/S) is 395.79 on November 15, 2024, which is -54.38% below the current Price to Sales Ratio (P/S).
BerGenBio ASA average Price to Sales Ratio (P/S) for the last 52 weeks is 1,404.77.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Oslo Stock Exchange: BGBIO.OL

BerGenBio ASA

CEO	Mr. Martin Olin
IPO Date	April 7, 2017
Location	Norway
Headquarters	Jonas Lies vei 91
Employees	15
Sector	Health Care
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.

Key trends

Past 5 years